Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays

Infection and Immunity

Volumn 81, Issue 6, 2013, Pages 1880-1888

  Pohl, Mary Ann ^a   Rivera, Johanna ^a   Nakouzi, Antonio ^a   Chow, Siu Kei ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BASE SEQUENCE; CELL LINE; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION, PASSIVE; MACROPHAGES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS;

EID: 84877823353     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01328-12     Document Type: Article

References (39)

1. Leppla SH. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 79:3162-3166.
2. Tonello F, Montecucco C. 2009. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol. Aspects Med. 30:431-438.
3. Turnbull PC. 2000. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr. Opin. Infect. Dis. 13:113-120.
4. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW, Jr, Gibbs PH, Friedlander AM. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
5. Baillie L, Townend T, Walker N, Eriksson U, Williamson D. 2004. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol. Med. Microbiol. 42:267-270.
6. Taft SC, Weiss AA. 2008. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol. 15:71-75.
7. Chitlaru T, Altboum Z, Reuveny S, Shafferman A. 2011. Progress and novel strategies in vaccine development and treatment of anthrax. Immunol. Rev. 239:221-236.
8. Cybulski RJ, Jr, Sanz P, O'Brien AD. 2009. Anthrax vaccination strategies. Mol. Aspects Med. 30:490-502.
9. Schneemann A, Manchester M. 2009. Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol. 4:35-43.
10. Casadevall A, Dadachova E, Pirofski LA. 2004. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2:695-703.
11. Chen Z, Moayeri M, Purcell R. 2011. Monoclonal antibody therapies against anthrax. Toxins 3:1004-1019.
12. Saylor C, Dadachova E, Casadevall A. 2009. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27(Suppl 6):G38-G46.
13. Chow SK, Casadevall A. 2012. Monoclonal antibodies and toxins-a perspective on function and isotype. Toxins 4:430-454.
14. Lim NK, Kim JH, Oh MS, Lee S, Kim SY, Kim KS, Kang HJ, Hong HJ, Inn KS. 2005. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. 73:6547-6551.
15. Little SF, Leppla SH, Friedlander AM. 1990. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1606-1613.
16. Staats HF, Alam SM, Scearce RM, Kirwan SM, Zhang JX, Gwinn WM, Haynes BF. 2007. In vitro and in vivo characterization of anthrax antiprotective antigen and anti-lethal factor monoclonal antibodies after pas-sive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 75:5443-5452.
17. Zhao P, Liang X, Kalbfleisch J, Koo HM, Cao B. 2003. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum. Antibodies 12:129-135.
18. Kulshreshtha P, Bhatnagar R. 2011. Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Mol. Immunol. 48:1958-1965.
19. Moayeri M, Leppla SH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30:439-455.
20. Brossier F, Levy M, Landier A, Lafaye P, Mock M. 2004. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 72:6313-6317.
21. Chen Z, Moayeri M, Crown D, Emerson S, Gorshkova I, Schuck P, Leppla SH, Purcell RH. 2009. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect. Immun. 77:3902-3908.
22. de StGroth SF. 1980. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 35:1-21.
23. Rivera J, Nakouzi A, Abboud N, Revskaya E, Goldman D, Collier RJ, Dadachova E, Casadevall A. 2006. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect. Immun. 74:4149-4156.
24. Abboud N, Chow SK, Saylor C, Janda A, Ravetch J, Scharff M, Casadevall A. 2010. A requirement for Fc R in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 207:2395-2405.
25. Torres M, Fernandez-Fuentes N, Fiser A, Casadevall A. 2007. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J. Biol. Chem. 282:13917-13927.
26. Abboud N, De Jesus M, Nakouzi A, Cordero RJ, Pujato M, Fiser A, Rivera J, Casadevall A. 2009. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies. J. Biol. Chem. 284:25077-25086.
27. Eliopoulos GM, Moellering RC. 1991. Antimicrobial combinations, 3rd ed. The Williams & Wilkins Co., Baltimore, MD.
28. Nguyen MH, Barchiesi F, McGough DA, Yu VL, Rinaldi MG. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
29. Franzot SP, Casadevall A. 1997. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 41:331-336.
30. Bragg TS, Robertson DL. 1989. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene 81:45-54.
31. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 99:11346-11350.
32. Nguyen ML, Terzyan S, Ballard JD, James JA, Farris AD. 2009. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect. Immun. 77:4714-4723.
33. Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P. 1997. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 185:685-694.
34. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20: 597-601.
35. Mahlandt BG, Klein F, Lincoln RE, Haines BW, Jones WI, Jr, Friedman RH. 1966. Immunologic studies of anthrax. IV. Evaluation of the immunogenicity of three components of anthrax toxin. J. Immunol. 96:727-733.
36. Muller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, Kliemt J, Meslin FX, Franka R, Rupprecht CE, Tordo N, Wanderler AI, Kieny MP. 2009. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl. Trop. Dis. 3:e542. doi:10.1371/journal.pntd.0000542.
37. Little SF, Webster WM, Fisher DE. 2011. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. FEMS Immunol. Med. Microbiol. 62:11-22.
38. Ngundi MM, Meade BD, Little SF, Quinn CP, Corbett CR, Brady RA, Burns DL. 2012. Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action. Clin. Vaccine Immunol. 19:731-739.
39. Chow SK, Smith C, MacCarthy T, Pohl MA, Bergman A, Casadevall A. Disease-enhancing antibodies improve the activity of toxin-neutralizing antibodies. Cell Host Microbe, in press.